Prof Deenan Pillay

Photo

Personal Profile

Name: Deenan Pillay Email: d.pillay@ucl.ac.uk
Title: Prof Tel: 0207 679 6362
Department: Div of Infection & Immunity Fax:
Position: Reader in Virology Address: Cruciform Building, Gower Street, London, WC1E 6BT
Research Domain: Experimental Medicine, Global Health, Infection, Immunology & Inflammation, Personalised Medicine, Populations & Lifelong Health Web Page:  

Profile

Research Description

Our work aims to explore the virological, clinical and epidemiological consequences of HIV drug resistance, and the nature of HIV transmission. We utilise multiple disciplines, including population assessments of drug resistance, molecular phylogeny, and in vitro models of viral replication. Since the HIV epidemic is a global problem, we also focus on antretroviral viral rollout in the resource poor world, in particular assessing the implications of treatment on the emergence of escape mutants, and the impact on future response to therapy. I also Head HIV and Antiretrovirals at the Centre for Infections, Health protection Agency, where we host a WHO Specialist Laboratory within the HIV Drug resistance network. Our work is funded by the MRC, Wellcome Trust and EU. The latter involves coordinating a large integrated European network on HIV and HIV Drug Resistance (CHAIN).

Research Activities

CMV Pathogenesis and Development of Vaccines

Epidemiology of HIV infection

HIV

Hepatitis-HIV co-infection

Host and Pathogen Genomics

Infection response through virus genomics (ICONIC)

pediatric sepsis

Education Description

UCL Collaborators

Prof Paul Griffiths; Prof Peter Coveney; Prof Steve Morris; Prof Amanda Mocroft; Prof Mala Maini; Prof Richard Tedder; Prof Nigel Klein; Prof Donald Peebles; Dr Richard Gilson; Prof Andrew Phillips; Prof Robin Callard; Dr Mona Bajaj-Elliot; Prof Caroline Sabin; Prof Chris Boshoff; Dr Richard Milne; Prof Christine Orengo; Prof Greg Towers

External Collaborators

Publications

    2014

    • Phillips A, Cambiano V, Nakagawa F, Magubu T, Miners A, Ford D, Pillay D, De Luca A, Lundgren J, Revill P (2014). Cost-Effectiveness of HIV Drug Resistance Testing to Inform Switching to Second Line Antiretroviral Therapy in Low Income Settings.. PLoS One, 9(10), e109148 - . doi:10.1371/journal.pone.0109148
    • Dennis AM, Herbeck JT, Brown AL, Kellam P, de Oliveira T, Pillay D, Fraser C, Cohen MS (2014). Phylogenetic studies of transmission dynamics in generalized HIV epidemics: An essential tool where the burden is greatest?. J Acquir Immune Defic Syndr, , - . doi:10.1097/QAI.0000000000000271
    • Watters S, Aasa-Chapman M, Mlcochova P, Grant P, Pillay D, Gupta R (2014). Assessment of viral diversity during viral rebound in a HIV-1 elite controller. HIV MEDICINE, 15, 46 - 47.
    • Hodcroft E, Hadfield JD, Fearnhill E, Phillips A, Dunn D, O'Shea S, Pillay D, Leigh Brown AJ, on behalf of the UK HIV Drug Resistance Database and the UK CHIC Study (2014). The Contribution of Viral Genotype to Plasma Viral Set-Point in HIV Infection.. PLoS Pathog, 10(5), e1004112 - . doi:10.1371/journal.ppat.1004112
    • Huntington S, Thorne C, Anderson J, Newell ML, Taylor GP, Pillay D, Hill T, Tookey P, Sabin C, UK Collaborative HIV Cohort (UK CHIC) Study , National Study of HIV in Pregnancy and Childhood (NSHPC) (2014). Response to antiretroviral therapy (ART): comparing women with previous use of zidovudine monotherapy (ZDVm) in pregnancy with ART naïve women.. BMC Infect Dis, 14(1), 127 - . doi:10.1186/1471-2334-14-127
    • Goodall RL, Dunn DT, Pattery T, van Cauwenberge A, Nkurunziza P, Awio P, Ndembi N, Munderi P, Kityo C, Gilks CF, Kaleebu P, Pillay D, DART Virology Group and Trial Teams (2014). Phenotypic and genotypic analyses to guide selection of reverse transcriptase inhibitors in second-line HIV therapy following extended virological failure in Uganda.. J Antimicrob Chemother, 69(7), 1938 - 1944. doi:10.1093/jac/dku052
    • Cambiano V, Bertagnolio S, Jordan MR, Pillay D, Perriëns JH, Venter F, Lundgren J, Phillips A (2014). Predicted levels of HIV drug resistance: potential impact of expanding diagnosis, retention, and eligibility criteria for antiretroviral therapy initiation.. AIDS, 28 Suppl 1, S15 - S23. doi:10.1097/QAD.0000000000000082
    • Frost SD, Pillay D (2014). Understanding drivers of phylogenetic clustering in molecular epidemiological studies of HIV.. J Infect Dis, , - . doi:10.1093/infdis/jiu563
    • Sutherland KA, Mbisa JL, Cane PA, Pillay D, Parry CM (2014). Contribution of Gag and protease to variation in susceptibility to protease inhibitors between different strains of subtype B human immunodeficiency virus type 1. JOURNAL OF GENERAL VIROLOGY, 95, 190 - 200. doi:10.1099/vir.0.055624-0
    • El Bouzidi K, Grant P, Edwards S, Benn P, Pillay D, Waters L, Nastouli E (2014). Pooled specimens for HIV viral load monitoring: cheaper but is it reliable?. Clin Infect Dis, , - . doi:10.1093/cid/ciu562
    • Hue S, Brown AE, Ragonnet-Cronin M, Lycett SJ, Dunn DT, Fearnhill E, Dolling DI, Pozniak A, Pillay D, Delpech VC, Leigh-Brown AJ (2014). Phylogenetic analyses reveal HIV-1 infections between men misclassified as heterosexual transmissions.. AIDS, , - . doi:10.1097/QAD.0000000000000383
    • Kityo C, Gibb DM, Gilks CF, Goodall RL, Mambule I, Kaleebu P, Pillay D, Kasirye R, Mugyenyi P, Walker AS, Dunn DT, DART Trial Team (2014). High Level of Viral Suppression and Low Switch Rate to Second-Line Antiretroviral Therapy among HIV-Infected Adult Patients Followed over Five Years: Retrospective Analysis of the DART Trial.. PLoS One, 9(3), e90772 - . doi:10.1371/journal.pone.0090772

    2013

    • Titanji BK, Aasa-Chapman M, Pillay D, Jolly C (2013). Protease inhibitors effectively block cell-to-cell spread of HIV-1 between T cells. Retrovirology, 10(1), 161 - 161. doi:10.1186/1742-4690-10-161
    • Touloumi G, Pantazis N, Pillay D, Paraskevis D, Chaix M-L, Bucher HC, Kuecherer C, Zangerle R, Kran A-MB, Porter K, EuroCoord CASCADEC (2013). Impact of HIV-1 Subtype on CD4 Count at HIV Seroconversion, Rate of Decline, and Viral Load Set Point in European Seroconverter Cohorts. CLINICAL INFECTIOUS DISEASES, 56(6), 888 - 897. doi:10.1093/cid/cis1000
    • Klein N, Sefe D, Jacobsen M, Jones H, Mosconi I, Zanchetta M, De Rossi A, Castro H, Walker AS, Gibb DM, Bernardi S, Pillay D, Giaquinto C (2013). The Immunological and Virological Consequences of Planned Treatment Interruptions in Children with HIV Infection. PLoS ONE, 8(10), - . doi:10.1371/journal.pone.0076582
    • Pillay D, Albert J, Bertagnolio S, Boucher C, Brun-Vezinet F, Clotet B, Giaquinto C, Perno CF (2013). Implications of HIV drug resistance on first- and second-line therapies in resource-limited settings: report from a workshop organized by the Collaborative HIV and Anti-HIV Drug Resistance Network.. Antivir Ther, , - . doi:10.3851/IMP2650
    • Pursuing Later Treatment Option II (PLATO II) Project Team of the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) , Costagliola D, Ledergerber B, Torti C, van Sighem A, Podzamczer D, Mocroft A, Dorrucci M, Masquelier B, de Luca A, Jansen K, De Wit S, Obel N, Fätkenheuer G, Touloumi G, Mussini C, Castagna A, Stephan C, García F, Zangerle R, Duval X, Perez-Hoyos S, Meyer L, Ghosn J, Fabre-Colin C, Kjaer J, Chêne G, Grarup J, Phillips A, Lodwick R, Torti C, Dorrucci M, Günthard HF, Michalik C, Chrysos G, Castagna A (2013). Predictors of CD4(+) T-cell counts of HIV type 1-infected persons after virologic failure of all 3 original antiretroviral drug classes.. J Infect Dis, 207(5), 759 - 767. doi:10.1093/infdis/jis752
    • Huntington SE, Thorne C, Bansi LK, Anderson J, Newell ML, Taylor GP, Pillay D, Hill T, Tookey PA, Sabin CA, UK Collaborative HIV Cohort (UK CHIC) Study and the National Study of HIV in Pregnancy and Childhood (NSHPC) (2013). Predictors of pregnancy and changes in pregnancy incidence among HIV-positive women accessing HIV clinical care.. AIDS, 27(1), 95 - 103. doi:10.1097/QAD.0b013e3283565df1
    • Martin SA, Cane PA, Pillay D, Mbisa JL (2013). The drug susceptibility and viral fitness of recombinant viruses expressing patient-derived integrase genes are significantly affected by co-evolved multidrug-resistant protease and reverse transciptase genes.
    • Titanji BK, Aasa-Chapman M, Jolly C, Pillay D (2013). Protease inhibitors are effective at inhibiting cell-to-cell HIV-1 transfer.
    • Cotten M, Lam TT, Watson SJ, Palser AL, Petrova V, Grant P, Pybus OG, Rambaut A, Guan Y, Pillay D, Kellam P, Nastouli E (2013). Full-Genome Deep Sequencing and Phylogenetic Analysis of Novel Human Betacoronavirus. EMERGING INFECTIOUS DISEASES, 19(5), 736 - 742. doi:10.3201/eid1905.130057
    • Gupta RK, Goodall RL, Ranopa M, Kityo C, Munderi P, Lyagoba F, Mugarura L, Gilks CF, Kaleebu P, Pillay D, DART Virology Group and Trial Team (2013). High Rate of HIV Re-suppression After Viral Failure on First Line Antiretroviral Therapy in the Absence of Switch to Second Line.. Clin Infect Dis, , - . doi:10.1093/cid/cit933
    • Dolling DI, Dunn DT, Sutherland KA, Pillay D, Mbisa JL, Parry CM, Post FA, Sabin CA, Cane PA, Database UKHIVDR, Study UKCHIVC (2013). Low frequency of genotypic resistance in HIV-1-infected patients failing an atazanavir-containing regimen: a clinical cohort study. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 68(10), 2339 - 2343. doi:10.1093/jac/dkt199
    • Bertagnolio S, Perno CF, Vella S, Pillay D (2013). The Impact of HIV Drug Resistance on the Selection of First- and Second-Line ART in Resource-Limited Settings. JOURNAL OF INFECTIOUS DISEASES, 207, S45 - S48. doi:10.1093/infdis/jit121
    • Price H, Gilson R, Dunn D, Pillay D, Bani-Sadr F, de Vries-Sluijs T, Jain MK, Kuzushita N, Mauss S, Núñez M, Nüesch R, Peters M, Reiberger T, Stephan C, Tan L (2013). Suppression of HBV by Tenofovir in HBV/HIV Coinfected Patients: A Systematic Review and Meta-Analysis. PLoS ONE, 8(7), - . doi:10.1371/journal.pone.0068152
    • Yebra G, Holguín A, Pillay D, Hué S (2013). Phylogenetic and demographic characterization of HIV-1 transmission in Madrid, Spain.. Infect Genet Evol, 14, 232 - 239. doi:10.1016/j.meegid.2012.12.006
    • Low AJ, Konate I, Nagot N, Weiss HA, Kania D, Vickerman P, Segondy M, Mabey D, Pillay D, Meda N, van de Perre P, Mayaud P (2013). Cervico-vaginal HIV-1 shedding in women taking antiretroviral therapy in Burkina Faso: A longitudinal study.. J Acquir Immune Defic Syndr, , - . doi:10.1097/QAI.0000000000000049

    2012

    • Gall A, Ferns B, Morris C, Watson S, Cotten M, Robinson M, Berry N, Pillay D, Kellam P (2012). Universal amplification, next-generation sequencing, and assembly of HIV-1 genomes.. J Clin Microbiol, 50(12), 3838 - 3844. doi:10.1128/JCM.01516-12
    • Hué S, Hassan AS, Nabwera H, Sanders EJ, Pillay D, Berkley JA, Cane PA (2012). HIV type 1 in a rural coastal town in Kenya shows multiple introductions with many subtypes and much recombination.. AIDS Res Hum Retroviruses, 28(2), 220 - 224. doi:10.1089/aid.2011.0048
    • Gilks CF, Walker AS, Dunn DT, Gibb DM, Kikaire B, Reid A, Musana H, Mambule I, Kasirye R, Robertson V, Ssali F, Spyer M, Pillay D, Yirrell D, Kaleebu P, Team DARTVGT (2012). Lopinavir/ritonavir monotherapy after 24 weeks of second-line antiretroviral therapy in Africa: a randomized controlled trial (SARA). ANTIVIRAL THERAPY, 17(7), 1363 - 1373. doi:10.3851/IMP2253
    • Price H, Bansi L, Sabin CA, Bhagani S, Burroughs A, Chadwick D, Dunn D, Fisher M, Main J, Nelson M, Pillay D, Rodger A, Taylor C, Gilson R, UK Collaborative HIV Cohort Hepatitis Group, Steering Committee (2012). Hepatitis B virus infection in HIV-positive individuals in the UK collaborative HIV cohort (UK CHIC) study.. PLoS One, 7(11), e49314 - . doi:10.1371/journal.pone.0049314
    • Mbisa JL, Hué S, Buckton AJ, Myers RE, Duiculescu D, Ene L, Oprea C, Tardei G, Rugina S, Mardarescu M, Floch C, Notheis G, Zöhrer B, Cane PA, Pillay D (2012). Phylodynamic and phylogeographic patterns of the HIV type 1 subtype F1 parenteral epidemic in Romania.. AIDS Res Hum Retroviruses, 28(9), 1161 - 1166. doi:10.1089/AID.2011.0390
    • (2012). Time trends in drug resistant HIV-1 infections in the United Kingdom up to 2009: multicentre observational study. Bmj, 345, e5253 - . doi:10.1136/bmj.e5253
    • von Wyl V, Cambiano V, Jordan MR, Bertagnolio S, Miners A, Pillay D, Lundgren J, Phillips AN (2012). Cost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoring.. PLoS One, 7(8), e42834 - . doi:10.1371/journal.pone.0042834
    • Huntington SE, Bansi LK, Pillay D, Hill T, Sabin CA, Thorne C, Newell M-L, Tookey PA, Anderson J, Taylor GP (2012). Using two on-going HIV studies to obtain clinical data from before, during and after pregnancy for HIV-positive women. BMC Medical Research Methodology, 12, - . doi:10.1186/1471-2288-12-110
    • Dolling D, Phillips AN, Delpech V, Pillay D, Cane PA, Crook AM, Shepherd J, Fearnhill E, Hill T, Dunn D, Database UKHIVDR, CHI UCHCU (2012). Evaluating the extent of potential resistance to pre-exposure prophylaxis within the UK HIV-1-infectious population of men who have sex with men. HIV MEDICINE, 13(5), 309 - 314. doi:10.1111/j.1468-1293.2011.00968.x
    • Huntington S, Thorne C, Anderson J, Newell M-L, Taylor G, Pillay D, Hill T, Tookey P, Sabin C (2012). Pregnancies among women seen for HIV-clinical care - predictors and trends over time.
    • Nakagawa F, Lodwick R, Costagliola D, van Sighem A, Torti C, Podzamczer D, Mocroft A, Ledergerber B, Dorrucci M, Cozzi-Lepri A, Jansen K, Masquelier B, Garcia F, De Wit S, Stephan C, Obel N, Faetkenheuer G, Castagna A, Sambatakou H, Mussini C, Ghosn J, Zangerle R, Duval X, Meyer L, Perez-Hoyos S, Colin CF, Kjaer J, Chene G, Grarup J, Phillips A, Castagna A, Costagliola D, Cozzi-Lepri A, De Luca A, De Wit S, de Wolf F, Dorrucci M, Duval X, Faetkenheuer G, Garcia F, Ghosn J, Guenthard H, Jansen K, Jorgensen L, Judd A, Ledergerber B, Lo Caputo S, Lodwick R, Masquelier B, Meyer L, Mocroft A, Mussini C, Noguera-Julian A, Obel N, Paraskevis D, Paredes R, Perez-Hoyos S, Phillips A, Pillay D, Podzamczer D, Ramos JT, Stephan C, Tookey PA, Torti C, Touloumi G, van Sighem A, Warsawski J, Zangerle R, Zangerle R, Touloumi G, Warszawski J, Meyer L, Dabis F, Krause MM, Ghosn J, Leport C, de Wolf F, Reiss P, Prins M, Buecher H, Sabin C, Gibb D, Faetkenheuer G, Del Amo J, Obel N, Thorne C, Mocroft A, Kirk O, Stephan C, Perez-Hoyos S, Noguera-Julian A, Antinori A, Monforte AD, Brockmeyer N, Ramos J, Battegay M, Rauch A, Mussini C, Tookey P, Casabona J, Miro JM, Castagna A, de Wit S, Goetghebuer T, Torti C, Teira R, Garrido M, Haerry D, Grp COHERE, Comm AW, Team PLATOIIP, Comm COHERES, Grp EAIDST (2012). Calendar Time Trends in the Incidence and Prevalence of Triple-Class Virologic Failure in Antiretroviral Drug-Experienced People With HIV in Europe. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 59(3), 294 - 299. doi:10.1097/QAI.0b013e31823fe66b
    • Gompels M, Dunn DT, Phillips A, Dooley D, De Burgh Thomas A, Anderson J, Post F, Pillay D, Gazzard B, Hill T, Johnson M, Gilson R, Bansi L, Easterbrook P, Fisher M, Walsh J, Orkin C, Ainsworth J, Leen C, Sabin C, UK Collaborative HIV Cohort (UK CHIC) Study (Appendix) (2012). Does discordancy between the CD4 count and CD4 percentage in HIV-positive individuals influence outcomes on highly active antiretroviral therapy?. J Infect Dis, 205(4), 540 - 547. doi:10.1093/infdis/jir380
    • Violari A, Cotton M, Otwombe K, Hunt G, Kalimashe M, Panchia R, Morris L, Pillay D, Babiker A, Gibb D (2012). Does early initiation of ART in infants affect virological and resistance outcomes? Data from the CHER trial after 6 years of follow-up. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 15, 7 - 7. doi:10.7448/IAS.15.6.18085
    • Tong CYW, Cane PA, Pillay D (2012). ARHAI: antiviral resistance. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 67, I65 - I72. doi:10.1093/jac/dks197
    • Gupta RK, Jordan MR, Sultan BJ, Hill A, Davis DH, Grehson J, Sawyer AW, Hamers RL, Ndembi N, Pillay D, Bertagnolio S (2012). Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis.. Lancet, 380(9849), 1250 - 1258. doi:10.1016/S0140-6736(12)61038-1
    • Dunn D, Babiker A, Pillay D (2012). Limitations of proposed novel trial design. Aids, 26(14), 1846 - 1847. doi:10.1097/QAD.0b013e32835732ee
    • Castro H, Pillay D, Sabin C, Dunn DT, Resi UKCGHIVD (2012). Effect of misclassification of antiretroviral treatment status on the prevalence of transmitted HIV-1 drug resistance. BMC MEDICAL RESEARCH METHODOLOGY, 12, - . doi:10.1186/1471-2288-12-30
    • Dennis AM, Hué S, Hurt CB, Napravnik S, Sebastian J, Pillay D, Eron JJ (2012). Phylogenetic insights into regional HIV transmission.. AIDS, 26(14), 1813 - 1822. doi:10.1097/QAD.0b013e3283573244
    • Barber TJ, Harrison L, Asboe D, Williams I, Kirk S, Gilson R, Bansi L, Pillay D, Dunn D, UK HIV Drug Resistance Database and UK Collaborative HIV Cohort (UK CHIC) Study Steering Committees (2012). Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor.. J Antimicrob Chemother, 67(4), 995 - 1000. doi:10.1093/jac/dkr569
    • Donegan KL, Walker AS, Dunn D, Judd A, Pillay D, Menson E, Lyall H, Tudor-Williams G, Gibb DM, Collaborative HIV Paediatric Study , UK HIV Drug Resistance Database (2012). The prevalence of darunavir-associated mutations in HIV-1-infected children in the UK.. Antivir Ther, 17(4), 599 - 603. doi:10.3851/IMP2015

    2011

    • McCormick AL, Parry CM, Crombe A, Goodall RL, Gupta RK, Kaleebu P, Kityo C, Chirara M, Towers GJ, Pillay D (2011). Impact of the N348I mutation in HIV-1 reverse transcriptase on nonnucleoside reverse transcriptase inhibitor resistance in non-subtype B HIV-1.. Antimicrob Agents Chemother, 55(4), 1806 - 1809. doi:10.1128/AAC.01197-10
    • Ferns RB, Kirk S, Bennett J, Cook PM, Williams I, Edwards S, Pillay D (2011). The dynamics of appearance and disappearance of HIV-1 integrase mutations during and after withdrawal of raltegravir therapy (vol 23, pg 2159, 2009). AIDS, 25(15), 1937 - 1937. doi:10.1097/QAD.0b013e32834bbbc7
    • Hughes RA, Sterne JA, Walsh J, Bansi L, Gilson R, Orkin C, Hill T, Ainsworth J, Anderson J, Gompels M, Dunn D, Johnson MA, Phillips AN, Pillay D, Leen C, Easterbrook P, Gazzard B, Fisher M, Sabin CA (2011). Long-term trends in CD4 cell counts and impact of viral failure in individuals starting antiretroviral therapy: UK Collaborative HIV Cohort (CHIC) study.. HIV Med, 12(10), 583 - 593. doi:10.1111/j.1468-1293.2011.00929.x
    • Gray ER, Garson JA, Breuer J, Edwards S, Kellam P, Pillay D, Towers GJ (2011). No evidence of XMRV or related retroviruses in a London HIV-1-positive patient cohort.. PLoS One, 6(3), e18096 - . doi:10.1371/journal.pone.0018096
    • Garvey L, Winston A, Walsh J, Post F, Porter K, Gazzard B, Fisher M, Leen C, Pillay D, Hill T, Johnson M, Gilson R, Anderson J, Easterbrook P, Bansi L, Orkin C, Ainsworth J, Phillips AN, Sabin CA, UK Collaborative HIV Cohort CHIC (2011). HIV-associated central nervous system diseases in the recent combination antiretroviral therapy era. EUR J NEUROL, 18(3), 527 - 534. doi:10.1111/j.1468-1331.2010.03291.x
    • Garvey L, Winston A, Walsh J, Post F, Porter K, Gazzard B, Fisher M, Leen C, Pillay D, Hill T, Johnson M, Gilson R, Anderson J, Easterbrook P, Bansi L, Orkin C, Ainsworth J, Palfreeman A, Gompels M, Phillips AN, Sabin CA, UK Collaborative HIV Cohort (CHIC) study (2011). Antiretroviral therapy CNS penetration and HIV-1-associated CNS disease.. Neurology, 76(8), 693 - 700. doi:10.1212/WNL.0b013e31820d8b0b
    • Zazzi M, Kaiser R, Sönnerborg A, Struck D, Altmann A, Prosperi M, Rosen-Zvi M, Petroczi A, Peres Y, Schülter E, Boucher CA, Brun-Vezinet F, Harrigan PR, Morris L, Obermeier M, Perno CF, Phanuphak P, Pillay D, Shafer RW, Vandamme AM, van Laethem K, Wensing AM, Lengauer T, Incardona F (2011). Prediction of response to antiretroviral therapy by human experts and by the EuResist data-driven expert system (the EVE study).. HIV Med, 12(4), 211 - 218. doi:10.1111/j.1468-1293.2010.00871.x
    • Cozzi-Lepri A, Prosperi MC, Kjær J, Dunn D, Paredes R, Sabin CA, Lundgren JD, Phillips AN, Pillay D, EuroSIDA Study , United Kingdom CHIC/United Kingdom HDRD Study (2011). Can linear regression modeling help clinicians in the interpretation of genotypic resistance data? An application to derive a lopinavir-score.. PLoS One, 6(11), e25665 - . doi:10.1371/journal.pone.0025665
    • Barber TJ, Geretti AM, Anderson J, Schwenk A, Phillips AN, Bansi L, Gilson R, Hill T, Walsh J, Fisher M, Johnson M, Post F, Easterbrook P, Gazzard B, Palfreeman A, Orkin C, Leen C, Gompels M, Dunn D, Delpech V, Pillay D, Sabin CA, UK CHIC Study Steering Committee (2011). Outcomes in the first year after initiation of first-line HAART among heterosexual men and women in the UK CHIC Study.. Antivir Ther, 16(6), 805 - 814. doi:10.3851/IMP1818
    • Gupta RK, Sultan B, Hill A, Haley T, Pillay D, Jordan MR, Bertagnolio S (2011). Prevalence of drug resistance in untreated HIV-1-infected individuals in low- and middle-income countries: a systematic review and meta-analysis.
    • Buckton AJ, Harris RJ, Pillay D, Cane PA (2011). HIV type-1 drug resistance in treatment-naive patients monitored using minority species assays: a systematic review and meta-analysis. ANTIVIR THER, 16(1), 9 - 16. doi:10.3851/IMP1687
    • Mbisa JL, Gupta RK, Kabamba D, Mulenga V, Kalumbi M, Chintu C, Parry CM, Gibb DM, Walker SA, Cane PA, Pillay D (2011). The evolution of HIV-1 reverse transcriptase in route to acquisition of Q151M multi-drug resistance is complex and involves mutations in multiple domains. RETROVIROLOGY, 8, - . doi:10.1186/1742-4690-8-31
    • Huntington SE, Bansi LK, Thorne C, Anderson J, Newell ML, Taylor GP, Pillay D, Hill T, Tookey PA, Sabin CA, UK Collaborative HIV Cohort (UK CHIC) Study and the National Study of HIV in Pregnancy and Childhood (NSHPC) (2011). Treatment switches during pregnancy among HIV-positive women on antiretroviral therapy at conception.. AIDS, 25(13), 1647 - 1655. doi:10.1097/QAD.0b013e32834982af
    • Buckton AJ, Prabhu D, Motamed C, Harris RJ, Hill C, Murphy G, Parry JV, Johnson JA, Lowndes CM, Gill N, Pillay D, Cane PA (2011). Increased detection of the HIV-1 reverse transcriptase M184V mutation using mutation-specific minority assays in a UK surveillance study suggests evidence of unrecognized transmitted drug resistance.. HIV Med, 12(4), 250 - 254. doi:10.1111/j.1468-1293.2010.00882.x
    • Parry CM, Kolli M, Myers RE, Cane PA, Schiffer C, Pillay D (2011). Three residues in HIV-1 matrix contribute to protease inhibitor susceptibility and replication capacity.. Antimicrob Agents Chemother, 55(3), 1106 - 1113. doi:10.1128/AAC.01228-10
    • Phillips AN, Pillay D, Garnett G, Bennett D, Vitoria M, Cambiano V, Lundgren J (2011). Effect on transmission of HIV-1 resistance of timing of implementation of viral load monitoring to determine switches from first to second-line antiretroviral regimens in resource-limited settings.. AIDS, 25(6), 843 - 850. doi:10.1097/QAD.0b013e328344037a
    • Vandekerckhove LPR, Wensing AMJ, Kaiser R, Brun-Vezinet F, Clotet B, De Luca A, Dressler S, Garcia F, Geretti AM, Klimkait T, Korn K, Masquelier B, Perno CF, Schapiro JM, Soriano V, Sonnerborg A, Vandamme A-M, Verhofstede C, Walter H, Zazzi M, Boucher CAB, Puchhammer-Stockl E, Van Laethem K, Ivanov IA, Beshkov DA, Lepej SZ, Kostrikis LG, Linka M, Nielsen C, Zilmer K, Liitsola K, Braun P, Daeumer M, Obermeier M, Paraskevis D, Minarovits J, Coughlin S, de Gascun C, Grossman Z, Balotta C, Rusconi S, Svicher V, Kolupajeva T, Griskevicius A, Schmit J-CC, Schuurman R, Asjo B, Horban AJW, Camacho RJ, Ene L, Otelea D, Stanojevic M, Stanekova D, Poljak M, Paredes R, Poveda E, Albert J, Yerly S, Cane P, Pillay D, Clinical ECG (2011). European guidelines on the clinical management of HIV-1 tropism testing. LANCET INFECTIOUS DISEASES, 11(5), 394 - 407. doi:10.1016/S1473-3099(10)70319-4
    • Dunn DT, Goodall RL, Munderi P, Kityo C, Ranopa M, Bacheler L, Van Houtte M, Gilks C, Kaleebu P, Pillay D, DART Virology Trial Team (2011). Residual Activity of Two HIV Antiretroviral Regimens Prescribed without Virological Monitoring. ANTIMICROB AGENTS CH, 55(10), 4575 - 4580. doi:10.1128/AAC.00580-11
    • Wittkop L, Günthard HF, de Wolf F, Dunn D, Cozzi-Lepri A, de Luca A, Kücherer C, Obel N, von Wyl V, Masquelier B, Stephan C, Torti C, Antinori A, García F, Judd A, Porter K, Thiébaut R, Castro H, van Sighem AI, Colin C, Kjaer J, Lundgren JD, Paredes R, Pozniak A, Clotet B, Phillips A, Pillay D, Chêne G, EuroCoord-CHAIN study group (2011). Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study.. Lancet Infect Dis, 11(5), 363 - 371. doi:10.1016/S1473-3099(11)70032-9

    2010

    • Kayondo JK, Ndembi N, Cane PA, Kityo C, Chirara M, Hue S, Goodall R, Dunn D, Kaleebu P, Pillay D, Mbisa JL, DART Virology Comm (2010). Different evolution of resistance uncovered by single-genome sequencing analysis of patients with long-term virological failure during continuous or interrupted antiretroviral therapy.
    • Price H, Asboe D, Pozniak A, Gazzard B, Fearnhill E, Pillay D, Dunn D, UK Collaborative Grp HIV Drug Resi , UK Collaborative HIV Cohort Study (2010). Positive and negative drug selection pressures on the N348I connection domain mutation: new insights from in vivo data. ANTIVIR THER, 15(2), 203 - 211. doi:10.3851/IMP1511
    • Chilton DN, Castro H, Lattimore S, Harrison LJ, Fearnhill E, Delpech V, Rice B, Pillay D, Dunn DT, UK Collaborative Grp HIV Drug Resi (2010). HIV type-1 drug resistance in antiretroviral treatment-naive adults infected with non-B subtype virus in the United Kingdom. ANTIVIR THER, 15(7), 985 - 991. doi:10.3851/IMP1658
    • Fletcher AJ, Hué S, Schaller T, Pillay D, Towers GJ (2010). Hare TRIM5α restricts divergent retroviruses and exhibits significant sequence variation from closely related lagomorpha TRIM5 genes.. J Virol, 84(23), 12463 - 12468. doi:10.1128/JVI.01514-10
    • Mbisa JL, Gupta RK, Cane PA, Kabamba D, Mulenga V, Kalumbi M, Chintu C, Gibb DM, Walker AS, Pillay D (2010). Identification of the phenotypic, genotypic and fitness correlates of non-B subtype HIV-1 NRTI resistance through longitudinal analysis of children with virological failure in the developing world.
    • Gupta RK, Kohli A, McCormick A, Towers G, Pillay D, Parry CM (2010). Full-length HIV-1 gag determines protease inhibitor susceptibility within in vitro assays.
    • Harrison L, Castro H, Cane P, Pillay D, Booth C, Phillips A, Geretti AM, Dunn D, UK Collaborative Grp HIV Drug , Chic, U (2010). The effect of transmitted HIV-1 drug resistance on pre-therapy viral load.
    • Harrison L, Castro H, Cane P, Pillay D, Booth C, Phillips A, Geretti AM, Dunn D, UK Collaborative Grp HIV Drug Resi , UK Collaborative HIV Cohort Study (2010). The effect of transmitted HIV-1 drug resistance on pre-therapy viral load. AIDS, 24(12), 1917 - 1922. doi:10.1097/QAD.0b013e32833c1d93
    • Fisher M, Pao D, Brown AE, Sudarshi D, Gill ON, Cane P, Buckton AJ, Parry JV, Johnson AM, Sabin C, Pillay D (2010). Determinants of HIV-1 transmission in men who have sex with men: a combined clinical, epidemiological and phylogenetic approach. AIDS, 24(11), 1739 - 1747. doi:10.1097/QAD.0b013e32833ac9c6
    • McCormick AL, Goodall RL, Joyce A, Ndembi N, Chirara M, Katundu P, Walker S, Yirrell D, Gilks CF, Pillay D, DART Virology Grp , Trial Team (2010). Lack of Minority K65R-Resistant Viral Populations Detected After Repeated Treatment Interruptions of Tenofovir/Zidovudine and Lamivudine in a Resource-Limited Setting. JAIDS-J ACQ IMM DEF, 54(2), 215 - 217. doi:10.1097/QAI.0b013e3181cc1058
    • Gupta RK, Ford D, Mulenga V, Walker AS, Kabamba D, Kalumbi M, Grant PR, Ferrier A, Pillay D, Gibb DM, Chintu C (2010). Drug resistance in human immunodeficiency virus type-1 infected Zambian children using adult fixed dose combination stavudine, lamivudine, and nevirapine.. Pediatr Infect Dis J, 29(8), e57 - e62. doi:10.1097/INF.0b013e3181e47609
    • Cozzi-Lepri A, Dunn D, Pillay D, Sabin CA, Fearnhill E, Geretti AM, Hill T, Kaye S, Bansi L, Smit E, Johnson M, Burns S, Gilson R, Cameron S, Easterbrook P, Zuckerman M, Gazzard B, Walsh J, Fisher M, Orkin C, Ainsworth J, Leen C, Gompels M, Anderson J, Phillips AN, Babiker A, Porter K, Sadiq T, Schwenk A, Mackie N, Winston A, Delpech V, UK Collaborative Grp HIV Drug Resi , UK CHIC Study Grp (2010). Long-Term Probability of Detecting Drug-Resistant HIV in Treatment-Naive Patients Initiating Combination Antiretroviral Therapy. CLIN INFECT DIS, 50(9), 1275 - 1285. doi:10.1086/651684
    • de Oliveira T, Pillay D, Gifford RJ, UK Collaborative Grp HIV Drug Resi (2010). The HIV-1 Subtype C Epidemic in South America Is Linked to the United Kingdom. PLOS ONE, 5(2), - . doi:10.1371/journal.pone.0009311
    • Ndembi N, Goodall RL, Dunn DT, McCormick A, Burke A, Lyagoba F, Munderi P, Katundu P, Kityo C, Robertson V, Yirrell DL, Walker AS, Gibb DM, Gilks CF, Kaleebu P, Pillay D, Dev Antiretroviral Treatment Afric (2010). Viral Rebound and Emergence of Drug Resistance in the Absence of Viral Load Testing: A Randomized Comparison between Zidovudine-Lamivudine plus Nevirapine and Zidovudine-Lamivudine plus Abacavir. J INFECT DIS, 201(1), 106 - 113. doi:10.1086/648590
    • Turner J, Bansi L, Gilson R, Gazzard B, Walsh J, Pillay D, Orkin C, Phillips A, Easterbrook P, Johnson M, Porter K, Schwenk A, Hill T, Leen C, Anderson J, Fisher M, Sabin C (2010). The prevalence of hepatitis C virus (HCV) infection in HIV-positive individuals in the UK - trends in HCV testing and the impact of HCV on HIV treatment outcomes. Journal of Viral Hepatitis, 17(8), 569 - 577.
    • Gupta RK, Kohli A, McCormick A, Towers G, Pillay D, Parry CM (2010). Full-length HIV-1 gag determines protease inhibitor susceptibility within in vitro assays.
    • Hué S, Gray ER, Gall A, Katzourakis A, Tan CP, Houldcroft CJ, McLaren S, Pillay D, Futreal A, Garson JA, Pybus OG, Kellam P, Towers GJ (2010). Disease-associated XMRV sequences are consistent with laboratory contamination.. Retrovirology, 7(1), 111 - . doi:10.1186/1742-4690-7-111
    • Lyagoba F, Dunn DT, Pillay D, Kityo C, Robertson V, Tugume S, Hakim J, Munderi P, Chirara M, Ndembi N, Goodall RL, Yirrell DL, Burke A, Gilks CF, Kaleebu P, DART Virology Trial Team (2010). Evolution of Drug Resistance During 48 Weeks of Zidovudine/Lamivudine/Tenofovir in the Absence of Real-Time Viral Load Monitoring. JAIDS-J ACQ IMM DEF, 55(2), 277 - 283.
    • Kayondo JK, Ndembi N, Cane PA, Kityo C, Chirara M, Hue S, Goodall R, Dunn D, Kaleebu P, Pillay D, Mbisa JL, DART Virology Comm (2010). Different evolution of resistance uncovered by single-genome sequencing analysis of patients with long-term virological failure during continuous or interrupted antiretroviral therapy.
    • Gupta RK, Kohli A, McCormick AL, Towers GJ, Pillay D, Parry CM (2010). Full-length HIV-1 Gag determines protease inhibitor susceptibility within in-vitro assays. AIDS, 24(11), 1651 - 1655. doi:10.1097/QAD.0b013e3283398216
    • Gupta RK, Kohli A, McCormick AL, Towers GJ, Pillay D, Parry CM (2010). Full-length HIV-1 Gag determines protease inhibitor susceptibility within in vitro assays.. AIDS, 24(11), 1651 - 1655.
    • Marks AJ, Pillay D, McLean AR (2010). The effect of intrinsic stochasticity on transmitted HIV drug resistance patterns.. J Theor Biol, 262(1), 1 - 13. doi:10.1016/j.jtbi.2009.09.017
    • Stohr W, Back D, Dunn D, Sabin C, Winston A, Gilson R, Pillay D, Hill T, Ainsworth J, Gazzard B, Leen C, Bansi L, Fisher M, Orkin C, Anderson J, Johnson M, Easterbrook P, Gibbons S, Khoo S, UK CHIC Steering Comm (2010). Factors influencing lopinavir and atazanavir plasma concentration. J ANTIMICROB CHEMOTH, 65(1), 129 - 137. doi:10.1093/jac/dkp408
    • Harrison L, Castro H, Cane P, Pillay D, Booth C, Phillips A, Geretti AM, Dunn D, UK Collaborative Grp HIV Drug Resi (2010). The effect of transmitted HIV-1 drug resistance on pre-therapy viral load.

    2009

    • Bansi L, Turner J, Gilson R, Post F, Gazzard B, Leen C, Anderson J, Porter K, Hill T, Fisher M, Ainsworth J, Pillay D, Johnson M, Winston A, Orkin C, Easterbrook P, Phillips A, Sabin C, on behalf of the UK Collaborative HIV Cohort CHIC Study (2009). Is 1 alanine transaminase >200 IU enough to define an alanine transaminase flare in HIV-infected populations? A new definition derived from a large cohort study. Journal of Acquired Immune Deficiency Syndromes, 52(3), 391 - 396. doi:10.1097/QAI.0b013e3181ab73cc
    • Price H, Dunn D, Asboe D, Pozniak A, Gazzard B, Pillay D, UK HIV Drug Resistance Database , UK Collaborative HIV Cohort CHIC S (2009). Positive and negative drug selection pressures on the N348I connection domain mutation: new insights from in vivo data.
    • Brown AE, Murphy G, Rinck G, Clewley JP, Hill C, Parry JV, Johnson AM, Pillay D, Gill ON (2009). Implications for HIV testing policy derived from combining data on voluntary confidential testing with viral sequences and serological analyses. Sexually Transmitted Infections, 85, 4 - 9. doi:10.1136/sti.2008.031831
    • Brown AE, Gifford RJ, Clewley JP, Kucherer C, Masquelier B, Porter K, Balotta C, Back NKT, Bruun Jorgensen L, de Mendoza C, Bhaskaran K, Gill ON, Johnson AJ, Pillay D (2009). Phylogenetic reconstruction of transmission events from individuals with acute HIV infection: Toward more-rigorous epidemiological definitions. The Journal of Infectious Diseases, 199, 427 - 431. doi:10.1086/596049
    • Bansi L, Sabin C, Gilson R, Gazzard B, Leen C, Anderson J, Dunn D, Hill T, Fisher M, Ainsworth J, Pillay D, Johnson M, Walsh J, Orkin C, Easterbrook P, Gompels M, Phillips A (2009). Virological response to initial antiretroviral regimens containing abacavir or tenofovir. The Journal of Infectious Diseases, 200, 710 - 714.
    • Geretti AM, Harrison L, Green H, Sabin C, Hill T, Fearnhill E, Pillay D, Dunn D (2009). Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy. Clinical Infectious Diseases, 48, 1296 - 1305.
    • Bower M, Fisher M, Hill T, Reeves I, Walsh J, Orkin C, Phillips A, Bansi L, Gilson R, Easterbrook P, Johnson M, Gazzard B, Leen C, Pillay D, Schwenk A, Anderson J, Porter K, Gompels M, Sabin CA, for the UK Collaborative HIV Cohort CHIC Study (2009). CD4 counts and the risk of systemic non-Hodgkin’s lymphoma in individuals with HIV in the UK.. Haematologica, 94(6), 875 - 880. doi:10.3324/haematol.2008.002691
    • Gilson R, Man S-L, Copas A, Rider A, Forsyth S, Hill T, Bansi L, Porter K, Gazzard B, Orkin C, Pillay D, Schwenk A, Johnson M, Easterbrook P, Walsh J, Fisher M, Leen C, Anderson J, Sabin CA, for the UK Collaborative HIV Cohort CHIC Study Group (2009). Discordant responses on starting highly active antiretroviral therapy: suboptimal CD4 increases despite early viral suppression in the UK Collaborative HIV Cohort (UK CHIC) Study. HIV Medicine, 11(2), 152 - 160. doi:10.1111/j.1468-1293.2009.00755.x
    • Gupta RK, Ford D, Kabamba D, Mulenga V, Kalumbi M, Kalengo C, Chileshe R, Grant P, Kirk S, Mbasa J, Thomason M, Ferrier A, Chintu C, Gibb DM, Pillay D, Walker AS (2009). Dynamics of accumulation of drug resistance mutations in the absence of virological monitoring in HIV-1-infected Zambian children using adult Triomune (fixed-dose combination d4T, 3TC and NVP).
    • Mbisa JL, Gupta RK, Cane PA, Kabamba D, Mulenga V, Kalumbi M, Chintu C, Gibb DM, Walker AS, Pillay D (2009). Dynamics of emergence and linkage of HIV reverse transcriptase Q151M MDR complex in children within first-line antiretroviral rollout uncovered by single-genome sequencing.
    • Parry CM, Cane P, Pillay D (2009). Identification of HIV-1 matrix determinants of fitness compensation in a protease inhibitor resistant virus.
    • Soriano V, Perno CF, Kaiser R, Calvez V, Gatell JM, di Perri G, Pillay D, Rockstroh J, Geretti AM (2009). When and how to use maraviroc in HIV-infected patients. AIDS, 23(18), 2377 - 2385. doi:10.1097/QAD.0b013e328332d32d
    • Gupta RK, Mlcochova P, Pelchen-Matthews A, Petit SJ, Mattiuzzo G, Pillay D, Takeuchi Y, Marsh M, Towers GJ (2009). Simian immunodeficiency virus envelope glycoprotein counteracts tetherin/BST-2/CD317 by intracellular sequestration.. Proc Natl Acad Sci U S A, 106(49), 20889 - 20894. doi:10.1073/pnas.0907075106
    • Ferns RB, Kirk S, Bennett J, Cook PM, Williams I, Edwards S, Pillay D (2009). The dynamics of appearance and disappearance of HIV-1 integrase mutations during and after withdrawal of raltegravir therapy.. AIDS, 23(16), 2159 - 2164. doi:10.1097/QAD.0b013e32832ec4ae
    • Kandathil AJ, Kannangai R, Abraham OC, Rupali P, Pulimood SA, Verghese VP, Grant P, Pillay D, Sridharan G (2009). The frequency of HIV-1 drug resistance mutations among treatment-naive individuals at a tertiary care centre in south India. INT J STD AIDS, 20(8), 522 - 526. doi:10.1258/ijsa.2008.008403
    • Gupta RK, Hill A, Sawyer AW, Cozzi-Lepri A, von Wyl V, Yerly S, Lima VD, Günthard HF, Gilks C, Pillay D (2009). Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis.. Lancet Infect Dis, 9(7), 409 - 417. doi:10.1016/S1473-3099(09)70136-7
    • Kandathil AJ, Kannangai R, Verghese VP, Pulimood SA, Rupali P, Sridharan G, Grant P, Pillay D, Abraham OC (2009). Drug resistant mutations detected by genotypic drug resistance testing in patients failing therapy in clade C HIV-1 infected individuals from India. INDIAN J MED MICROBI, 27(3), 231 - 236. doi:10.4103/0255-0857.53205
    • Gifford RJ, Liu TF, Rhee SY, Kiuchi M, Hue S, Pillay D, Shafer RW (2009). The calibrated population resistance tool: standardized genotypic estimation of transmitted HIV-1 drug resistance. BIOINFORMATICS, 25(9), 1197 - 1198. doi:10.1093/bioinformatics/btp134
    • Hué S, Gifford RJ, Dunn D, Fernhill E, Pillay D, UK Collaborative Group on HIV Drug Resistance (2009). Demonstration of sustained drug-resistant human immunodeficiency virus type 1 lineages circulating among treatment-naïve individuals.. J Virol, 83(6), 2645 - 2654. doi:10.1128/JVI.01556-08
    • Buckton AJ, Prabhu DP, Cane PA, Pillay D (2009). No evidence for cross-contamination of dried blood spots excised using an office hole-punch for HIV-1 drug resistance genotyping. J ANTIMICROB CHEMOTH, 63(3), 615 - 616. doi:10.1093/jac/dkn518
    • Gupta KR, Hue S, Schaller T, Verschoor E, Pillay D, Towers GJ (2009). Mutation of a single residue renders human tetherin resistant to HIV-1 Vpu-mediated depletion.. PloS Pathogens, 5(e1000443), - .
    • Parry CM, Kohli A, Boinett CJ, Towers GJ, McCormick AL, Pillay D (2009). Gag determinants of fitness and drug susceptibility in protease inhibitor-resistant human immunodeficiency virus type 1. Journal of Virology, 83(18), 9094 - 9101. doi:10.1128/JVI.02356-08
    • Buckton AJ, Prabhu D, Murphy G, Parry JV, Johnson JA, Pillay D, Cane PA (2009). The potential role of minority mutation assays in surveillance of transmitted drug resistance.
    • Ndembi N, McCormick A, Kaleebu P, Pillay D, Bacheler L, Pattery T, Goodall R, Dunn D, Katundu P, Chirara M, Gilks C, Yirrell D, Munderi P, Kityo C (2009). Phenotypic data to guide selection of reverse transcriptase inhibitors in second-line therapy following extended virological failure in Uganda.
    • Pao D, Pillay D, Fisher M (2009). Potential impact of early antiretroviral therapy on transmission. CURR OPIN HIV AIDS, 4(3), 215 - 221. doi:10.1097/COH.0b013e328329c5ca
    • Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, Kiuchi M, Heneine W, Kantor R, Jordan MR, Schapiro JM, Vandamme AM, Sandstrom P, Boucher CAB, van de Vijver D, Rhee SY, Liu TF, Pillay D, Shafer RW (2009). Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 Update. PLOS ONE, 4(3), - . doi:10.1371/journal.pone.0004724
    • Gupta RK, Gibb DM, Pillay D (2009). Management of paediatric HIV-1 resistance.. Curr Opin Infect Dis, 22(3), 256 - 263.

    2008

    • Soriano V, Geretti AM, Perno CF, Fatkenheuer G, Pillay D, Reynes J, Tambussi G, Calvez V, Alcami J, Rockstroh J (2008). Optimal use of maraviroc in clinical practice. AIDS, 22(17), 2231 - 2240. doi:10.1097/QAD.0b013e3283136d95
    • Mihailidis C, Dunn D, Pillay D, Pozniak A (2008). Effect of isolated V118I mutation in reverse transcriptase on response to first-line antiretroviral therapy. AIDS, 22(3), 427 - 430.
    • Phillips AN, Pillay D, Miners A, Gilks CF, Lundgren JD (2008). Monitoring of antiretroviral therapy in low-resource settings - Reply. LANCET, 372(9635), 289 - 289.
    • Chakraborty R, Smith CJ, Dunn D, Green H, Duong T, Doerholt K, Riordon A, Lyall H, Tookey P, Butler K, Sabin CA, Gibb D, Pillay D, Collaborative HIV Paediat Study CH , UK Collaborative Grp HIV Drug Resi (2008). HIV-1 drug resistance in HIV-1-infected children in the United Kingdom from 1998 to 2004. PEDIATR INFECT DIS J, 27(5), 457 - 459. doi:10.1097/INF.0b013e3181646d6f
    • Phillips AN, Pillay D, Miners AH, Bennett DE, Gilks CF, Lundgren JD (2008). Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observations alone: a computer simulation model. The Lancet, 371(9622), 1443 - 1451.
    • Grover D, Copas A, Green H, Edwards SG, Dunn DT, Sabin C, Phillips A, Allen E, Pillay DOBOTUKCGOHIVDRAUKCHIVCSUKCHIC (2008). What is the risk of mortality following diagnosis of multidrug-resistant HIV-1?. Journal of Antimicrobial Chemotherapy, 61(3), 705 - 713. doi:10.1093/jac/dkm522
    • Bansi LK, Benzie AA, Phillips AN, Portsmouth S, Hill T, Leen C, Schwenk A, Johnson M, Anderson J, Gilson R, Easterbrook P, Gazzard B, Fisher M, Orkin C, Porter K, Pillay D, Taylor GP, Walsh JC, Sabin CA, for the UK Collaborative HIV Cohort CHIC Study (2008). Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression?. AIDS, 22(3), 349 - 356. doi:10.1097/QAD.0b013e3282f4709a
    • Stöhr W, Back D, Dunn D, Sabin C, Winston A, Gilson R, Pillay D, Hill T, Ainsworth J, Pozniak A, Leen C, Bansi L, Fisher M, Orkin C, Anderson J, Johnson M, Easterbrook P, Gibbons S, Khoo S, on behalf of the Liverpool TDM Database and the UKCHIC Study (2008). Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication. Antiviral Therapy, 13(5), 675 - 685.
    • Cozzi-Lepri A, Dunn D, Pillay D, Sabin C, Fearnhill E, Phillips A, and the UKHIV Drug Resistance Database and UKCHIC Study Groups (2008). Long-term probability of detecting HIV drug resistance in drug-naïve patients starting currently recommended first-line combination ART..
    • Parry CM, Kohli A, Pillay D (2008). Gag-protease inter-relationships in drug resistance and viral fitness.
    • Gupta RK, Hill A, Sawyer AW, Cozzi-Lepri A, Phillips A, von Wyl V, Yerly S, Gunthard HF, Pillay D (2008). Emergence of drug resistance after failure of first-line HAART is associated with intensity of virological monitoring: a systematic analysis of cohort and trial data specifically addressing the WHO public health approach to antiretroviral therapy.
    • Phillips A, Pillay D, Miners A, Bennett D, Gilks CF, Lundgren JD (2008). Predicting the effects on resistance of lack of viral load monitoring in resource-limited settings.
    • Dunn D, Geretti AM, Green H, Fearnhill E, Pozniak A, Churchill D, Pillay D, Sabin C, Phillips A, UK Collaborative Grp , HIV Drug Resistance & UK Collabora (2008). Population trends in the prevalence and patterns of protease resistance related to exposure to unboosted and boosted protease inhibitors. ANTIVIR THER, 13(6), 771 - 777.
    • Gupta R, Hill A, Sawyer AW, Pillay D (2008). Emergence of drug resistance in HIV type-1 infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials. Clinical Infectious Diseases, 47(5), 712 - 722.
    • Buckton AJ, Bissett SL, Myers RE, Beddows S, Edwards S, Cane PA, Pillay D (2008). Development and optimization of an internally controlled dried blood spot assay for surveillance of human immunodeficiency virus type-1 drug resistance. J ANTIMICROB CHEMOTH, 62(6), 1191 - 1198. doi:10.1093/jac/dkn412
    • Green H, Tilston P, Fearnhill E, Pillay D, Dunn DT, UK Collaborative Grp HIV Drug (2008). The impact of different definitions on the estimated rate of transmitted HIV drug resistance in the United Kingdom. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 49(2), 196 - 204.
    • Hirsch MS, Günthard HF, Schapiro JM, Brun-Vézinet F, Clotet B, Hammer SM, Johnson VA, Kurizkes DR, Mellors JW, Pillay D, Yeni PG, Jacobsen DM, Richman DD (2008). Antiretoviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society - USA panel. Clinical Infectious Diseases, 47(2), 266 - 285.
    • Johnson VA, Brun-Vézinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD (2008). Update of the drug resistant mutations in HIV-1: Spring 2008. Topics in HIV Medicine, 16(1), 62 - 68.
    • Myers RE, Pillay D (2008). Analysis of natural sequence variation and covariation in Human Immunodeficiency Virus Type-1 integrase. Journal of Virology, , - .

    2007

    • Phillips AN, Leen C, Wilson A, Anderson J, Dunn D, Schwenk A, Orkin C, Hill T, Fisher M, Walsh J, Pillay D, Bansi L, Gazzard B, Easterbrook P, Gilson R, Johnson M, Sabin CA, on behalf of the UK Collaborative HIV Cohort CHIC Study (2007). Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study. The Lancet, 370(9603), 1923 - 1928. doi:10.1016/S0140-6736(07)61815-7
    • Buckton AJ, Bissett SL, Myers RE, Beddows S, Pillay D (2007). Factors determining efficacy of HIV-1 drug resistance genotyping from dried blood spots within an internally-controlled assay system.
    • Pillay D (2007). Antiretroviral resistance in the developing world. Journal of HIV Therapy, 12(4), 95 - 96.
    • Phillips AN, Sabin C, Pillay D, Lundgren JD (2007). HIV in the UK 1980-2006: reconstruction using a model of HIV infection and the effect of antiretroviral therapy. HIV Medicine, 8(8), 536 - 546. doi:10.1111/j.1468-1293.2007.00507.x
    • Phillips AN, Gilson R, Easterbrook P, Fisher M, Gazzard B, Johnson M, Walsh J, Leen C, Orkin C, Anderson J, Pillay D, Delpech V, Schwenk A, Dunn D, Gompels M, Hill T, Porter K, Babiker A, Sabin C (2007). HIV diagnosis at CD4 count above 500 Cells/mm(3) and progression to below 350 Cells/mm(3) without Antiretroviral therapy. JAIDS-J ACQ IMM DEF, 46(3), 275 - 278.
    • Phillips AN, Gazzard B, Gilson R, Easterbrook P, Johnson M, Walsh J, Leen C, Fisher M, Orkin C, Anderson J, Pillay D, Delpech V, Sabin C, Schwenk A, Dunn D, Gompels M, Hill T, Porter K, Babiker A, UK Collaborative HIV Cohort Study (2007). Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count. AIDS, 21(13), 1717 - 1721. doi:10.1097/QAD.0b013e32827038bf
    • Abraham AM, Kavitha S, Joseph P, George R, Pillay D, Malathi J, Jesudason MV, Sridharan G (2007). Aciclovir resistance among Indian strains of herpes simplex virus as determined using a dye uptake assay. Indian Journal of Medical Microbiology, 25(3), 260 - 262.
    • Gupta RK, Pillay D (2007). HIV resistance and the developing world. INT J ANTIMICROB AG, 29(5), 510 - 517. doi:10.1016/j.ijantimicag.2007.01.003
    • Green H, Gibb DM, Walker AS, Pillay D, Butler K, Candeias F, Castelli-Gattinara G, Compagnucci A, Della Negra M, de Rossi A, Feiterna-Sperling C, Giaquinto C, Harper L, Levy J, Saidi Y, Wintergerst U (2007). Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children. AIDS, 21(8), 947 - 955.
    • Lee KJ, Shingadia D, Pillay D, Walker AS, Riordan A, Menson E, Duong T, Tudor-Williams G, Gibb DM, on BOTCHIVPSCHIPSSC (2007). Transient viral load increases (ãblipsà) in HIV infected children in the UK and Ireland: what do they mean?. Antiviral Therapy, In Press IC IDM, - .
    • Myers RE, Pillay D (2007). HIV-1 integrase sequence variation and covariation.
    • Kohli A, Parry C, Pillay D (2007). Exploring plasma-virus-derived gag-protease interrelationships in drug resistance and fitness landscape.
    • Buckton AJ, Bissett SL, Myers RE, Beddows S, Pillay D (2007). Factors determining efficacy of HIV-1 drug resistance genotyping from dried blood spots within an internally-controlled assay system.
    • Myers RE, Pillay D (2007). HIV-1 integrase sequence variation and covariation.
    • Dunn D, Pillay D (2007). UK HIV drug resistance database: background and recent outputs. Journal of HIV Therapy, 12(4), 97 - 98.
    • Pillay D, Rambaut A, Geretti AM, Brown AJ (2007). HIV phylogenetics. BMJ (Clinical Research Ed.), 335(7618), 460 - 461.
    • Pillay D, Rambaut A, Geretti AM, Brown AJL (2007). HIV phylogenetics - Criminal convictions relying solely on this to establish transmission are unsafe. BRIT MED J, 335(7618), 460 - 461. doi:10.1136/bmj.39315.398843.BE
    • Pillay D (2007). The priorities for antiviral drug resistance surveillance and research. Journal of Antimicrobial Chemotherapy, 60(Suppl 1), i57 - 58.
    • Edwards SG, Grover D, Scott C, Tedder RS, Pillay D, Copas A, Miller RF (2007). Cytomegalovirus viral load testing of blood using quantitative polymerase chain reaction in acutely unwell HIV-1-positive patients lacks diagnostic utility. International Journal of STD and AIDS, 18(5), 321 - 323.
    • Pillay D, Fisher M (2007). Primary HIV infection, phylogenetics and antiretroviral prevention. The Journal of Infectious Diseases, 195(7), 924 - 926.
    • Shafer RW, Rhee SY, Pillay D, Miller V, Sandstrom P, Schapiro JM, Kuritzkes DR, Bennett D (2007). HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS, 21(2), 215 - 223.
    • Kohli A, Parry C, Pillay D (2007). Exploring plasma-virus-derived gag-protease interrelationships in drug resistance and fitness landscape.
    • Gifford RJ, de Oliveira T, Rambaut A, Pybus OG, Dunn D, Vandamme AM, Kellam P, Pillay D, UK CGOHDR (2007). Phylogenetic surveillance of viral genetic diversity and the evolving molecular epidemiology of human immunodeficiency virus type 1. Journal of Virology, 81(23), 13050 - 13056.

    2006

    • Kaleebu P, Pillay D, Walker AS, Robertson V, Gale C, Enzama R, Yirrell D, Lyagoba F, Kityo C, Munderi P, Reid A, Gibb DM, Bray D, Burke A, Ait-Khaled M, Darbyshire JH, Muygenyi P, Hakim J, Grosskurth H, Gilks C, DART VGATT (2006). Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa. AIDS, 20(10), 1391 - 1399.
    • Pillay D, Bhaskaran K, Jurriaans S, Prins M, Masquelier B, Dabis F, Gifford R, Nielsen C, Pedersen C, Balotta C, Rezza G, Ortiz M, de Mendoza C, Kucherer C, Poggensee G, Gill J, Porter K (2006). The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy.. AIDS, 20(1), 21 - 28.
    • Gifford R, de Oliveira T, Rambaut A, Myers RE, Gale CV, Dunn D, Shafer R, Vandamme AM, Kellam P, pillay D, UK CGOHDR (2006). Assessment of automated genotyping protocols as tools for surveillance of HIV-1 genetic diversity. AIDS, 13;20(11), 1521 - 1529.
    • Green H, Gibb DM, Compagnucci A, Giacomet V, De Rossi A, Harper L, Sadi Y, Castelli-Gattinara G, Pillay D, Babiker AG, Aboulker JP, Lyall H, Bacheler LT, Walker AS, DebrZ A, Rosso R, Burger DM, Della Negra M, Dunn DT, Giaquinto C, on BOTPENFTTOAIDSPENTA (2006). A randomized controlled trial of genotypic HIV drug resistance testing in HIV-1-infected children: the PERA (PENTA 8)Trial. Antiviral Therapy, 11IC IDM QTR4 RP, 857 - 867.
    • Pillay D, Sabin C, Pao D, Dunn D, Fisher M (2006). What is the drug resistance mutational infectious burden in an HIV-1 prevalent cohort and the relationship to incidence of transmitted resistance?.
    • Lewis F, Fearnhill E, Murray R, Pillay D, Dunn D, Leigh Brown A, UK Drug Resistance Collaboration (2006). Bayesian graphical models in the analysis of HIV drug resistance data from the UK HIV Drug Resistance Database.
    • Boffito M, Pillay D, Wilkins E (2006). Management of advanced HIV disease: resistance, antiretroviral brain penetration and malignancies. International Journal of Clinical Practice, 60(9), 1098 - 106.
    • Johnson VA, Brun-Vezinet F, Clotet B, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD (2006). Update of the drug resistance mutations in HIV-1: Fall 2006.. Topics in HIV Medicine, , - .
    • Bezemer D, de Ronde A, Prins M, Porter K, Gifford R, Pillay D, Masquelier B, Fleury H, Dabis F, Back N, Jurriaan S, van der Hoek L, CASCADE Collaboration (2006). Evolution of transmitted HIV-1 with drug-resistance mutations in the absence of therapy: effects on CD4+ T-cell countand HIV-1 RNA load.. Antiviral Therapy, 11(2), 173 - 178.
    • Snoeck J, Kantor R, Shafer RW, van Laethem K, Deforche K, Carvalho AP, Wynhoven B, Soares MA, Cane P, Clarke J, Pillay C, Sirivichayakul S, Ariyoshi K, Holguin A, Rudich H, Rodrigues R, Bouzas MB, Brun-vezinet F, Reid C, Cahn P, Brigido LF, Grossman Z, Soriano V, Sugiura W, Phanuphak P, Morris L, Weber J, Pillay DEA (2006). discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent. Antimicrobial Agents and Chemotherapy, 50(2), 694 - 701.
    • Gifford RJM, Kellam P, Dunn D, Pillay D, UK Coll Grp HIV Drug Resist (2006). The impact of structural and functional constraints acting at the nucleic acid level on the evolution of drug resistance in HIV-1.
    • Shafer RW, Rhee SY, Pillay D, Dalwani A, Miller V, Sandstrom P, Schapiro JM, Kuritzkes DR, Bennett D (2006). HIV-1 reverse transcriptase (RT) mutations for HIV drug resistance surveillance and epidemiology: application to published studies of primary infection.

    2005

    • Grover D, Allen L, Edwards SG, Green H, Copas A, Forsyth S, Pillay D, UK Collaborative Grp HIV Drug , UK Collaborative HIV Cohort Study (2005). Predictors of death, and response to therapy in patients with multi (three)-class drug resistant (MDR) HIV in the UK..
    • Phillips AN, Dunn D, Sabin C, Pozniak A, Matthias R, Geretti AM, Clarke J, Churchill D, Williams I, Hill T, Green H, Porter K, Scullard G, Johnson M, Easterbrook P, Gilson R, Fisher M, Loveday C, Gazzard B, Pillay D (2005). Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice.. AIDS, 19(5), 487 - 494.
    • Sadiq ST, Taylor S, Copas AJ, Bennett J, Kaye S, Drake SM, Kirk S, Pillay D, Weller IV (2005). The effects of urethritis on seminal plasma HIV-1 RNA loads in homosexual men not receiving antiretroviral therapy.. Sexually Transmitted Infections, 81(2), 120 - 123. doi:10.1136/sti.2004.010249
    • Sadiq ST, Taylor S, Copas AJ, Bennett J, Drake SM, Kirk S, Pillay D, Weller IV (2005). The effects of urethritis on Seminal Plasma HIV-1 RNA loads in HIV positive patients not receiving antiretroviral therapy.. Sexually Transmitted Diseases, 81, 120 - 123.
    • Pillay D, Green H, Matthias R, Dunn D, Phillips A, Sabin C, Evans B (2005). Estimating HIV-1 drug resistance in antiretroviral-treated individuals in the United Kingdom. The Journal of Infectious Diseases, 192(6), 967 - 973.
    • Chilton D, Dervisevic S, Pillay D, Rider A, Copas A, Miller RF, Edwards SG (2005). Determinants of HIV drug resistance mutations in plasma virus after treatment interruption.. AIDS, 19(18), 2174 - 2175.
    • Cane P, Chrystie I, Dunn D, Evans B, Geretti AM, Green H, Phillips A, Pillay D, Porter K, Pozniak A, Sabin C, Smit E, Weber J, Zuckerman M, Hill T (2005). Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ, 331(7529), 1358 - .
    • Masquelier B, Bhaskaran K, Pillay D, Gifford R, Balestre E, Jorgensen LB, Pedersen C, van der Hoek L, Prins M, Balotta C, Longo B, Kucherer C, Poggensee G, Ortiz M, de Mendoza C, Gill J, Fleury H, Porter K (2005). Prevalence of transmitted HIV-1 drug resistance and the role of resistance algorithms: data from seroconverters in the CASCADE collaboration from 1987 to 2003. JAIDS: Journal of Acquired Immune Deficiency Syndromes, 40(5), 505 - 511.
    • Grover D, Allen L, Edwards SG, Green H, Copas A, Forsyth S, Pillay D, on behalf of the UK Collaborative Group on HIV Drug Resistance and UK Collaborative HIV Cohort Study UKCHIC (2005). Predictors of death, and response to therapy in patients with multi (three)-class drug resistant (MDR) HIV in the UK..
    • Gifford R, Pillay D, UK HIV-1 Drug Resistance Grp (2005). Utilisation of HIV-1 subtype specific consensus sequences to explore treatment related mutational patterns within and between subtypes.
    • Hue S, Clewley JP, Cane PA, Pillay D (2005). Investigation of HIV-1 transmission events by phylogenetic methods: requirement for scientific rigour.. AIDS, 19(4), 449 - 450.
    • Johnson VA, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, Pillay D, Schapiro J, Telenti A, Richman D (2005). Update of the Drug Resistance Mutations in HIV-1: 2005.. Topics in HIV Medicine, 13(1), 51 - 57.
    • Xu L, Pozniak A, Wildfire A, Stanfield-Oakley SA, Mosier SM, Ratcliffe D, Workman J, Joall A, Myers R, Smit E, Cane PA, Greenberg ML, Pillay D (2005). Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41.. Antimicrobial Agents and Chemotherapy, 49(3), 1113 - 1119.
    • Dunn DT, Green H, Loveday C, Rinehart A, Pillay D, Fisher M, McCormack S, Babiker AG, Darbyshire JH Evaluation of Resistance Assays ERA Trial INVESTIGATORS (2005). A randomized controlled trial of the value of phenotypic testing in addition to genotypic testing for HIV drug resistance: evaluation of resistance assays (ERA) trial investigators.. JAIDS: Journal of Acquired Immune Deficiency Syndromes, 38(5), 553 - 559.
    • Kantor R, Katzenstein DA, Efron B, Carvalho AP, Wynhoven B, Cane P, Clarke J, Sirivichayakul S, Soares MA, Snoeck J, Pillay C, Rudich H, Rodrigues R, Holguin A, Ariyoshi K, Bouzas MB, Cahn P, Sugiura W, Soriano V, Brigido LF, Grossman Z, Morris L, Vandamme AM, Tanuri A, Phanuphak P, Weber JN, Pillay D, Harrigan PR, Camacho R, Schapiro JM, Shafer RW (2005). Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. PLOS MED, 2(4), 325 - 337. doi:10.1371/journal.pmed.0020112
    • Hué S, Pillay D, Clewley JP, Pybus OG (2005). Genetic analysis reveals the complex structure of HIV-1 transmission within defined risk groups. Proceedings of the National Academy of Sciences of the United States of America, 102(12), 4425 - 4429. doi:10.1073/pnas.0407534102
    • Pao D, Fisher M, Hue S, Dean G, Murphy G, Cane PA, Sabin CA, Pillay D (2005). Transmission of HIV-1 during primary infection: relationship to sexual risk and sexually transmitted infections.. AIDS, 19(1), 85 - 90.
    • Babiker AG, Breckenridge A, Darbyshire JH, Dunn DT, Fakoya A, Fisher M, Leigh Brown A, Loveday C, McCormack S, Pillay D, Poppa A, Rinehart A, Verbiest W, Williams I, Era SC (2005). A randomised controlled trial of the clinical utility of genotypic resistance testing in patients with limited prior exposure to antiretroviral drugs. HIV Clinical Trials, 6(4), 183 - 186.
    • pillay D, parry J (2005). Multidrug resistant HIV and rapid progression of disease reported from New York.. Eurosurveillance, 24;10(2), - .
    • Grover D, Allen L, Pillay D, Green H, Copas A, Forsyth S, Edwards SG, on behalf of the UK Collaborative Group on HIV Drug Resistance and UK Collaborative HIV Cohort Study UKCHIC (2005). Virological and clinical outcomes in patients with multi (three)-class drug resistant (MDR) HIV in the UK..
    • Lewis F, Frost SDW, Pillay D, Mathews WC, Richman DD, Little SJ, Brown AJL (2005). Transmitted HIV drug resistance: effect of treatment intensification in limiting the epidemic.
    • Lewis F, Frost SDW, Pillay D, Mathews WC, Richman DD, Little SJ, Brown AJL (2005). Transmitted HIV drug resistance: effect of treatment intensification in limiting the epidemic.
    • Gifford R, Pillay D, UK Collaborat Grp HIV-1 Drug (2005). Utilisation of HIV-1 subtype specific consensus sequences to explore treatment related mutational patterns within and between subtypes.

    2004

    • Dunn DT, Green H, Matthias R, Woodburn P, Gifford R, Chrystie I, Zuckerman M, Geretti AM, Loveday C, Clark J, Pillay D, Cane P, Churchill D, Pozniak A, UK HIV Collaboarative Grp HIV (2004). Prevalence of reduced drug susceptibility in treatment-naive patients in the UK.
    • Mihailidis C, Dunn D, Pillay D, Pozniak A (2004). Transmission of HIV-1 containing V118I in reverse transcriptase does not compromise response to first line therapy.
    • Pao D, Andrady U, Clarke J, Dean G, Drake S, Fisher M, Green T, Kumar S, Murphy M, Tang A, Taylor S, White D, Underhill G, Pillay D, Cane P (2004). Long-Term Persistence of Primary Genotypic Resistance After HIV-1 Seroconversion. J ACQUIR IMMUNE DEFIC SYNDR, 37(5), 1570 - 1573.
    • Dumans AT, Soares MA, Machado ES, Hue S, Brindeiro RM, Pillay D, Tanuri A (2004). Synonymous genetic polymorphisms within Brazilian human immunodeficiency virus Type 1 subtypes may influence mutational routes to drug resistance. J INFECT DIS, 189(7), 1232 - 1238.
    • Phillips AN, Dunn D, Sabin C, Pozniak A, Matthias R, Geretti AM, Clarke J, Churchill D, Williams I, Hill T, Green H, Porter K, Scullard G, Johnson M, Easterbrook P, Gilson R, Fisher M, Loveday C, Gazzard B, Pillay D (2004). Risk of development of drug resistance in patients starting antiretroviral therapy with three or more drugs in routine clinical practice.
    • Johnson VA, Brun-Vezinet F, Clotet B, Conway B, D'Aquila RT, Demeter LM, Kuritzkes DR, Pillay D, Schapiro JM, Telenti A, Richman DD (2004). Update of the drug resistance mutations in HIV-1: 2004. TOP HIV MED, 12(4), 119 - 124.
    • Brun-Vezinet F, Costagliola D, Khaled MA, Calvez V, Clavel F, Clotet B, Haubrich R, Kempf D, King M, Kuritzkes D, Lanier R, Miller M, Miller V, Phillips A, Pillay D, Schapiro J, Scott J, Shafer R, Zazzi M, Zolopa A, DeGruttola V (2004). Clinically validated genotype analysis: guiding principles and statistical concerns. ANTIVIR THER, 9(4), 465 - 478.
    • Pillay D, Green H, Gazzard B, Pozniak A, Matthias R, Johnson M, Churchill D, Fisher M, Hill T, Geretti AM, Clarke J, Cane P, Loveday C, Scullard G, Easterbrook P, Porter K, Williams I, Gilson R, Sabin C, Phillips A, Dunn D, UK Collaborative Grp HIV Drug (2004). Estimating resistance in drug experienced patients in the UK.
    • Bhaskaran K, Pillay D, Walker AS, Fisher M, Hawkins D, Gilson R, McLean K, Porter K (2004). Do patients who are infected with drug-resistant HIV have a different CD4 cell decline after seroconversion? An exploratory analysis in the UK Register of HIV Seroconverters. AIDS, 18(10), 1471 - 1473.
    • Jeffrey K, Pillay D (2004). Diagnostic approaches. In Banatvala J, Pattison JR, Griffiths PD, Zuckerman A (Ed.), Principles and Practice of Clinical Virology (pp. - ). : Wiley and Sons.
    • Vandamme AM, Sonnerborg A, Ait-Khaled M, Albert J, Asjo B, Bacheler L, Banhegyi D, Boucher C, Brun-Vezinet F, Camacho R, Clevenbergh P, Clumeck N, Dedes N, De Luca A, Doerr HW, Faudon JL, Gatti G, Gerstoft J, Hall WW, Hatzakis A, Hellmann N, Horban A, Lundgren JD, Kempf D, Miller M, Miller V, Myers TW, Nielsen C, Opravil M, Palmisano L, Perno CF, Phillips A, Pillay D, Pumarola T, Ruiz L, Salminen M, Schapiro J, Schmidt B, Schmit JC, Schuurman R, Shulse E, Soriano V, Staszewski S, Vella S, Youle M, Ziermann R, Perrin L (2004). Updated European recommendations for the clinical use of HIV drug resistance testing. Antiviral Therapy, 9(6), 829 - 848.
    • Weiss RA, Dalgleish AG, Loveday C, Pillay D (2004). Immunodeficiency viruses. In Zuckerman AJ, Banatvala JE, Pattison JR, Griffiths PD, Schoub BD (Ed.), Principles and Practice of Clinical Virology (pp. 721 - 757). : John Wiley and Sons Ltd.
    • Herrero-Martinez E, Sabin CA, Lee CA, Jones IM, Pillay D, Emery VC (2004). The effect of highly active antiretroviral therapy for HIV on the anti-HCV specific humoral immune response. Journal of Medical Virology, 72(2), 187 - 193.
    • Scott P, Arnold E, Evans B, Pozniak A, Moyle G, Shahmenesh M, White D, Shirley J, Cane P, Pillay D (2004). Surveillance of HIV antiretroviral drug resistance in treated individuals in England: 1998-2000. J ANTIMICROB CHEMOTHER, 53(3), 469 - 473.
    • Cane PA, Aitkin C, Ward K, Clarke J, Parmar S, Zuckerman M, Smith M, Tilston P, O'Shea S, Pillay D (2004). Pilot scheme for performance assessment of HIV-1 genotypic resistance testing in the UK. COMMUN DIS PUBLIC HEALTH, 7(1), 24 - 29.
    • Hue S, Clewley JP, Cane PA, Pillay D (2004). HIV-1 pol gene variation is sufficient for reconstruction of transmissions in the era of antiretroviral therapy. AIDS, 18(5), 719 - 728.
    • Winston A, Pozniak A, Mandalia S, Gazzard B, Pillay D, Nelson M (2004). Which nucleoside and nucleotide backbone combinations select for the K65R mutation in HIV-1 reverse transcriptase. AIDS, 18(6), 949 - 951.
    • Tang JW, Pillay D (2004). Transmission of HIV-1 drug resistance. J CLIN VIROL, 30(1), 1 - 10.
    • Amin J, Kaye M, Skidmore S, Pillay D, Cooper DA, Dore GJ (2004). HIV and hepatitis C coinfection within the CAESAR study. HIV MED, 5(3), 174 - 179.
    • MacLennan C, Dunn G, Huissoon AP, Kumararatne DS, Martin J, O'Leary P, Thompson RA, Osman H, Wood P, Minor P, Wood DJ, Pillay D (2004). Failure to clear persistent vaccine-derived neurovirulent poliovirus infection in an immunodeficient man. The Lancet, 363(9420), 1509 - 1513. doi:10.1016/S0140-6736(04)16150-3
    • Pillay D (2004). Current patterns in the epidemiology of primary HIV drug resistance in North America and Europe. ANTIVIR THER, 9(5), 695 - 702.

    2003

    • Vaughan HE, Cane P, PILLAY D, Tedder RS (2003). Characterisation of HIV-1 Clades in the Caribbean using pol gene sequences.
    • Chakrabarti S, Milligan DW, PILLAY D, MACKINNON S, Holder K, Kaur N, McDonald D, Fegan CD, Waldmann H, Hale G, Rickinson A, Steven N (2003). Reconstitution of the Epstein-Barr virus-specific cytotoxic T-lymphocyte response following T-cell-depleted myeloablative and nonmyeloablative allogenic stem cell transplantation. BLOOD, 102, 839 - 842.
    • Tanuri A, Soares MA, Dumans AT, Hue S, Pillay D (2003). Synonomous genetic changes within subtype FHIV-1 may influence mutational routes to drug resistance.
    • Isaac A, PILLAY D (2003). New drugs for treating drug resistant HIV-1. Sexually Transmitted Diseases, 79(3), 176 - 178.
    • Morgan E, Pillay D, Cane P, Kleim JP, Tisdale M, Maguire M, Macmanus S, Yates P, Elston R (2003). The HIV-1 protease mutation K55R is associated with the presence of the M461/L mutation.
    • Pozniak A, Gazzard B, Anderson J, Babiker A, Churchill D, Collins S, Fisher M, Johnson M, Khoo S, Leen C, Loveday C, Moyle G, Nelson M, Peters B, Phillips A, Pillay D, Wilkins E, Williams I, Youle M (2003). British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Medicine, 4(Sup1), S1 - S41.
    • Nelson M, Portsmouth S, Stebbing J, Atkins M, Barr A, Matthews G, PILLAY D, Fisher M, Bower M, Gazzard B (2003). An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals. AIDS, 17(1), F7 - 10.
    • Balogun MA, Laurichesse H, Ramsay ME, Sellwood J, Westmoreland D, Paver WK, Pugh SF, Zuckerman M, PILLAY D (2003). Risk factors, clinical features and genotype distribution of diagnosed hepatitis C virus infections: a pilot for a sentinel laboratory-based surveillance. Communicable Disease and Public Health, 6(1), 34 - 39.
    • Taylor S, Cane P, Hue S, Xu L, Wrin T, Lie Y, Hellmann N, PILLAY D (2003). Identification of a Transmission Chain of HIV Type 1 Containing Drug Resistance-Associated Mutations. AIDS Research and Human Retroviruses, 19(5), 353 - 361.
    • Pillay D, Green H, UK Collaborative Grp HIV Drug Resi (2003). The UKHIV Drug Resistance Database: development and use for national surveillance.
    • Sabin CA, Wilkins E, Murphy M, Fisher M, de Ruiter A, Easterbrook PJ, Leen C, Vlahakis E, Cane PA, Li X, PILLAY D (2003). Drug resistance genotypes predict response to amprenavir-containing regimens in highly drug-experienced HIV-1-infected patients. Antiviral Therapy, 8(4), 301 - 308.
    • Taylor S, Sadiq ST, Weller I, Kaye S, Workman J, Cane PA, Bennett J, Copas AJ, Drake SM, PILLAY D (2003). Drug-resistant HIV-1 in the semen of men receiving antiretroviral therapy with acute sexually transmitted infections. Antiviral Therapy, 8(5), 479 - 483.
    • Gilleece Y, Torti C, Mandalia S, Gazzard BG, PILLAY D, Pozniak AL (2003). The prevalence of reduced zidovudine susceptibility in zidovudine-naive, antiretroviral-experienced HIV-1-infected patients. HIV Medicine, 4(4), 305 - 310.
    • Johnson VA, Brun-Vezinet F, Clotet B, Conway B, D'Aquila RT, Demeter LM, Kuritzkes DR, PILLAY D (2003). Drug resistance mutations in HIV-1. Topics in HIV Medicine, 11(6), 215 - 221.
    • Dervisevic S, PILLAY D (2003). Issues in diagnostic testing and monitoring in HIV/viral hepatitis co-infection. Journal of HIV Therapy, 8(4), 89 - 95.

    2002

    • Gibb DM, Walker AS, Kaye S, De Rossi A, Ait-Khaled M, Pillay D, Munoz-Fernandez MA, Loveday C, Compagnucci A, Dunn DT, Babiker AG (2002). Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral-naive HIV-1-infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (the PENTA 5 trial). ANTIVIR THER, 7(4), 293 - 303.
    • PILLAY D, Emery VC, MUTIMER D, Ogilvie MM, Carman W, Mutton K, Wreghitt T, Westmoreland D, Breuer J, Zuckerman M (2002). Guidelines for laboratory monitoring of treatment of persistent virus infections. Journal of Clinical Virology, 25(1), 73 - 92.
    • Pillay D, Walker AS, Gibb DM, de Rossi A, Kaye S, Ait-Khaled M, Munoz-Fernandez M, Babiker A, Paediat European Network Treatment (2002). Impact of human immunodeficiency virus type 1 subtypes on virologic response and emergence of drug resistance among children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 trial. JOURNAL OF INFECTIOUS DISEASES, 186(5), 617 - 625.
    • Sadiq ST, Taylor S, Kaye S, Bennett J, Johnstone R, Byrne P, Copas AJ, Drake SM, PILLAY D, Weller I (2002). The effects of antirectroviral therapy on HIV-1 RNA loads in seminal plasma in HIV positive patients with and without urethritis. AIDS, 16(2), 219 - 255. doi:10.1097/00002030-200201250-00011
    • Sadiq TS, Taylor S, Kaye S, Bennett J, Johnstone R, Byrne P, Copas AJ, Drake SM, PILLAY D, Weller I (2002). The effects of antiretroviral therapy on HIV-1 RNA loads in seminal plasma in HIV-Positive patients with and without urethritis. AIDS, 16(2), 219 - 225.

    2001

    • Miller V, Vandamme AM, Loveday C, Staszewski S, Lundgren J, Youle M, Ait-Khaled M, Boucher C, Brun-Vezinet F, Dedes N, Giaquinto C, Hertogs K, Houyez F, Perrin L, Pillay D, Schmit JC, Schuurman R, Lange J, Banhegyi D, Biondi G, Broekhuizen A, Bush-Donovan C, Camacho R, Carlier H, Clavel F, Clotet B, Clumeck N, Colebunders R, De Clerq K, De Jaegher JJ, De Schrijver G, De Smet K, Hall W, Harrigan R, Hatzakis A, Hellmann N, Hoetelmans R, Holtzer C, Katlama C, Larder D, Loriaux E, McCreedy B, Mulcahy F, Opravil M, Phillips A, Ruiz N, Shulse E, Sonnerborg A, Soriano V, Steel H, Vella S, Williams A, EuroGuidelines Grp HIV Resistance (2001). Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. AIDS, 15(3), 309 - 320.
    • Miller V, Vandamme AM, Loveday C, Staszewski S, Lundgren J, Youle M, Ait-Khaled M, Boucher C, Brun-Vezinet F, Dedes N, Giaquinto C, Hertogs K, Houyez F, Perrin L, PILLAY D, Schmit JC, Schuurman R, Lange J, Banhegyi D, Biondi G, Broekhuizen A, Bush-Donovan C, Camacho R, Carlier H, Clavel F, Clotet B, Clumeck N, Colebunders R, De Clerq K, De Jaegher JJ, De Schrijver G, De Smet K, Hall W, Harrigan R, Hatzakis A, Hellmann N, Hoetelmans R, Holtzer C, Katlama C, Larder D, Loriaux E, McCreedy B, Mulcahy F, Opravil M, Phillips A, Ruiz N, Shulse E, Sonnerborg A, Soriano V, Steel H, Vella S, Williams A (2001). Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. The EuroGUidelines Group for HIV resistance. AIDS, 15(3), 309 - 320.
    • Porter K, Pillay D, Cane P, Dean G, Churchill D, Baily G, Drake S, Fisher M (2001). Evidence for rising prevalence of HIV-1 drug resistance in primary infections in the UK. BMJ, 322, 1087 - 1088.
    • Taylor S, Reynolds H, Sabin CA, Drake SM, White DJ, Back DJ, PILLAY D (2001). Penetration of efavirenz into the male genital tract: drug concentrations and antiviral activity in semen and blood of HIV-1-infected men. AIDS, 15(15), 2051 - 2053.

    2000

    • PILLAY D, MUTIMER D, SINGHAL S, Turner A, WARD KN, WOOD M (2000). Management of herpesvirus infections following transplantation. Journal of Antimicrobial Chemotherapy, 45, 729 - 748.
    • Pillay D, Cane PA, Shirley J, Porter K, on behalf of the UK Register of HIV Seroconverters Steering Committee (2000). Detection of drug resistance associated mutations in HIV primary infection within the UK. AIDS, 14(7), 906 - 908.
    • Hoggard PG, Kewn S, Sales SD, Lloyd J, Maher B, Khoo SH, Wilkins E, Jones T, Pillay D, Sabin C, Back DJ (2000). Measurement of nucleoside analogue triphosphates by enzymatic assay in HIV patients in a clinical setting. AIDS, 14, S10 - S10.

    1999

    • Knowles WA, Pillay D, Johnson MA, Hand JF, Brown DWG (1999). Prevalence of long-term BK and JC excretion in HIV-infected adults and lack of correlation with serological markers. J MED VIROL, 59(4), 474 - 479.
    • Chakrabarti S, Steven N, Collingham K, Cassellas SA, Pillay D, Kaur N, Hale G, Mackinnon S, Milligan DW (1999). Viral reactivation and immune reconstitution following Campath 1H and fludarabine based non-myeloablative conditioning for allogeneic stem cell transplantation compared to Campath-based T cell depletion regimens: A preliminary report.. BLOOD, 94(10), 153A - 153A.

    1996

    • Kidd IM, Clark DA, Emery VC, Pillay D (1996). HHV-6 and HHV-7 in febrile convulsions of young children.

    1993

    • Kidd IM, Fox JC, Pillay D, Charman H, Griffiths PD, Emery VC (1993). Provision of prognostic information in immunocompromised patients by routine application of the polymerase chain reaction for cytomegalovirus. Transplantation, 56(4), 867 - 871.

    1992

    • Kidd IM, Emery V, Griffiths P, Pillay D (1992). Provision of prognostic information in immunocompromised patients by routine application of the polymerase chain reaction for cytomegalovirus.

    • Castro H, Dunn DT, Cane P, et al (). Persistence of transmitted HIV drug resistance mutations.